Durable complete response to PD-1 inhibitor in vesical calculus-associated squamous cell carcinoma: a case report
Tislelizumab monotherapy may be a viable option for surgery-ineligible or chemotherapy-intolerant calculus-associated bladder SCC. Definitive stone removal under immunological tumor control is feasible, supporting further exploration of PD-1 inhibitors in this rare subtype.
Authors
- Xiaojing Dong (ORCID: https://orcid.org/0000-0003-3842-6958)
- Hanghao Zhang
- Xiaobao Fu
- Ye Li (ORCID: https://orcid.org/0000-0002-9377-5504)
- Cheng Wang (ORCID: https://orcid.org/0000-0003-4823-1484)
- Su Zhang (ORCID: https://orcid.org/0000-0001-5962-1758)
- Yingjun Ma (ORCID: https://orcid.org/0000-0002-0958-0027)
Institutions
- Sichuan University (CN)
- West China Second University Hospital of Sichuan University (CN)
- Lanzhou University Second Hospital (CN)
- Tibet Autonomous Region People's Hospital (CN)
- Lanzhou City University (CN)
- Lanzhou University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-11-21
- DOI
- https://doi.org/10.3389/fimmu.2025.1688443
- Citations
- 1
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.01
Funders
- Lanzhou University